- Home
- CRSP
as 12-18-2024 10:35am EST
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
| Founded: | 2013 | Country: | Switzerland |
| Employees: | N/A | City: | ZUG |
| Market Cap: | 4.3B | IPO Year: | 2016 |
| Target Price: | $76.60 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Buy | Number of Analysts: | 18 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.90 | EPS Growth: | N/A |
| 52 Week Low/High: | $42.86 - $91.10 | Next Earning Date: | 11-05-2024 |
| Revenue: | $202,829,000 | Revenue Growth: | 19.31% |
| Revenue Growth (this year): | -95.61% | Revenue Growth (next year): | 758.18% |
Stock Insider Trading Activity of CRISPR Therapeutics AG (CRSP)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kulkarni Samarth | CRSP | Chief Executive Officer | Dec 2 '24 | Sell | $55.10 | 15,000 | $826,564.50 | 181,540 | |
| Kulkarni Samarth | CRSP | Chief Executive Officer | Nov 11 '24 | Sell | $55.85 | 30,000 | $1,668,678.36 | 181,540 | |
| Kulkarni Samarth | CRSP | Chief Executive Officer | Oct 13 '24 | Sell | $46.28 | 4,293 | $198,680.04 | 181,540 | |
| KASINGER JAMES R. | CRSP | General Counsel and Secretary | Oct 13 '24 | Sell | $46.28 | 1,089 | $50,398.92 | 62,597 |
Latest CRISPR Therapeutics AG News
CRSP Breaking Stock News: Dive into CRSP Ticker-Specific Updates for Smart Investing
Zacks
a day ago
3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025
Motley Fool
a day ago
2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?
Motley Fool
4 days ago
3 Things You Need to Know if You Buy CRISPR Therapeutics Today
BioPharma Dive
6 days ago
Editas to lay off staff after search for sickle cell partner comes up empty
Insider Monkey
7 days ago
Is CRISPR Therapeutics AG (CRSP) the Worst ARK Stock to Buy According to Short Sellers?
MT Newswires
9 days ago
CRISPR Therapeutics Says Trial Data Show CTX112 Has 'Potential' to Treat Malignancies
GlobeNewswire
9 days ago
CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting
Motley Fool
11 days ago
2 Biotech Stocks to Buy Hand Over Fist in December
Compare CRSP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRSP CRISPR Therapeutics AG - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.